Plant-derived anticancer agents

Biochemical Pharmacology

Volumn 53, Issue 2, 1997, Pages 121-133

  Pezzuto, John M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

cancer chemoprevention; cancer chemotherapy; cancer control; cancer prevention; chemoprevention formulation; disease prevention; drug discovery; natural product drugs; pharmacoeconomics

Indexed keywords

CAMPTOTHECIN; NAVELBINE; PACLITAXEL; PODOPHYLLOTOXIN; TENIPOSIDE; TOPOTECAN; VINCRISTINE; VINCRISTINE SULFATE;

ANTINEOPLASTIC ACTIVITY; BIOASSAY; CANCER; DATA BASE; DRUG DEVELOPMENT; DRUG ISOLATION; DRUG SCREENING; ECONOMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; NONHUMAN; PLANT; PRIORITY JOURNAL; REVIEW;

EID: 0031012054     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00654-5     Document Type: Note

References (64)

1. Farnsworth NR, Screening plants for new medicines. In: Biodiversity (Eds. Wilson EO and Peters FM), pp. 61-73. Academic Press, New York, 1988.
2. Balandrin MF, Kinghorn AD and Farnsworth NR, Plant-derived natural products in drug discovery and development: An overview. In: Human Medicinal Agents from Plants (ACS Symposium Series No. 534) (Eds. Kinghorn AD and Balandrin MF), pp. 2-12. American Chemical Society Books, Washington, DC, 1993.
3. Farnsworth NR and Morris RW, Higher plants: The sleeping giants for drug development. Am J Pharm 147: 46-52, 1976.
4. Farnsworth NR and Soejarto DD, Potential consequences of plant extinction in the United States on the current and future availability of prescription drugs. Econ Bot 39: 231-240, 1985.
5. Principe PP, Monetizing the pharmacological benefits of plants. In: Medicinal Plant Resources of the Tropical Forest (Eds. Balick MJ, Elisabetsky E and Laird SA), Chap. 14, pp. 191-218. Columbia University Press, New York, 1996.
6. O'Neill MJ and Lewis JA, The renaissance of plant research in the pharmaceutical industry. In: Human Medicinal Agents from Plants (ACS Symposium Series NO. 534) (Eds. Kinghorn AD and Balandrin MF), pp. 48-55. American Chemical Society Books, Washington, DC, 1993.
7. Heidelberger C, Chaudhuri NK, Dannenberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E and Scheiner J, Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 179: 663-666, 1957.
8. Cover illustration, Int J Pharmacognosy 33 (Suppl), 1995.
9. Farnsworth NR, Loub WD, Soejarto DD, Cordell GA, Quinn ML and Mulhoonand K, Computer services for research on plants for fertility regulation. Korean J Pharmacogn 12: 98-110, 1981.
10. Cordell GA, Beecher CCW and Pezzuto JM, Can ethnopharmacology contribute to the development of new anticancer drugs? J Ethnopharmacol 32: 117-133, 1991.
11. Loub WD, Farnsworth NR, Soejarto DD and Quinn ML, NAPRALERT: Computer-handling of natural products research data. J Chem Inf Comput Sci 25: 99-103, 1985.
12. Constant HL and Beecher CWW, A method for the dereplication of natural product extracts using electrospray HPLC/ MS. Nat Prod Lett 6: 193-196, 1995.
13. Constant HL, Capsaicinoid separation and the dereplication of natural product extracts. Ph.D. Thesis, University of Illinois at Chicago, Chicago, 1996.
14. Suffness M and Pezzuto JM, Assays for cytotoxicity and anti-tumor activity. In: Methods in Plant Biochemistry (Ed. Hostettmann K), Vol. 6, Chap. 4, pp. 71-133. Academic Press, London, 1991.
15. U.S. Bureau of the Census, Statistical Abstract of the United States 1993, 113th Ed. U.S. Government Printing Office, Washington, DC, 1993.
16. Heart and Stroke Facts: 1995 Statistical Supplement. American Heart Association, Dallas, TX, 1995.
17. Cancer Facts & Figures-1995. American Cancer Society, New York, 1995.
18. Diabetes Facts: The Direct and Indirect Costs of Diabetes in the United States. American Diabetes Association, Alexandria, VA, 1993.
19. Weiss KB, Gergen PJ and Hodgson TA, An economic evaluation of asthma in the United States. N Engl J Med 326: 862-866, 1992.
20. McClain JD, Good news. Income rise fastest in great lakes, plains states. Associated Press release taken from the Chicago Tribune, Section 2, p. 2, August 26, 1995.
21. Landefeld JS and Seskin EP, The economic value of life: Linking theory to practice. Am J Public Health 72: 555-556, 1982.
22. Goldman L, Gordon DJ, Rifkind BM, Hulley SB, Detsky AS, Goodman DS, Kinosian B and Weinstein MC, Cost and health implications of cholesterol lowering. Circulation 85: 1960-1968, 1992.
23. Bloom BS, Hillman AL, Fendrick AM, and Schwartz JS, A reappraisal of hepatitis B virus vaccination strategies using cost-effective analysis. Ann Intern Med 118: 298-306, 1993.
24. Lieu TA, Cochi SL, Black SB, Halloran ME, Shinefield HR, Holmes SJ, Wharton J and Washington AE, Cost-effectiveness of a routine varicella vaccination program for U.S. children. J Am Med Assoc 271: 375-381, 1994.
25. Pedersen TR and the Scandinavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet 344: 1383-1389, 1994.
26. Brown ML, Sensitivity analysis in the cost-effectiveness of breast cancer screening. Cancer 69 (Suppl): 1963-1967, 1992.
27. Celentano DD and de Lissovoy G, Assessment of cervical cancer screening and follow-up programs. Public Health Rev 17: 173-240, 1990.
28. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG and Detsky AS, Screening for prostate cancer. A decision analytic view. J Am Med Assoc 272: 773-780, 1994.
29. Sporn MB, Chemoprevention of cancer. Lancet 342: 1211-1213, 1993.
30. Greenwald P, Cullen JW and McKenna JW, Cancer prevention and control from research through applications. J Natl Cancer Inst 79: 389-400, 1987.
31. Greenwald P, Nixon DW, Malone WF, Kelloff GJ, Stern HR and Witkin KM, Concepts in cancer chemoprevention research. Cancer 65: 1483-1490, 1990.
32. Wattenberg LW, Chemoprophylaxis of carcinogenesis: A review. Cancer Res 26: 1520-1526, 1966.
33. Sporn MB, Dunlop NM, Newton DL and Smith JM, Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fedn Proc 35: 1332-1338, 1976.
34. Bjelke E, Dietary vitamin A and human lung cancer. Int J Cancer 15: 561-565, 1975.
35. Hirayama T, Diet and cancer. Nutr Cancer 1: 67-81, 1979.
36. Henderson BE, Ross RK, Shibata A, Hill-Paganini A and Yu MC, Environmental carcinogens and anticarcinogens. In: Cancer Chemoprevention (Eds. Wattenberg L, Lipkin M, Boone CW and Kelloff GJ), pp. 3-17. CRC Press, Boca Raton, 1992.
37. Boone CW, Kelloff GJ and Malone WE, Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: A review. Cancer Res 50: 2-9, 1990.
38. Havas S, Heimendinger J, Reynolds K, Baranowski T, Nicklas TA, Bishop D, Buller D, Sorensen G, Beresford SAA, Cowan A and Damron D, Five a day for better health: A new research initiative. J Am Diet Assoc 94: 32-36, 1994.
39. Zhang Y, Kensler TW, Cho C-G, Posner GH and Talalay P, Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci USA 91: 3147-3150, 1994.
40. Springen K and Hager M, Beyond vitamins. Newsweek, pp. 45-49, April 25, 1994.
41. Costa A, Santoro G and Assimakopoulos G, Cancer chemoprevention. A review of ongoing clinical studies. Acta Oncol 29: 657-663, 1990.
42. Wattenberg LW, Chemoprevention of cancer by naturally occurring and synthetic compounds. In: Cancer Chemoprevention (Eds. Wattenberg L, Lipkin M, Boone CW and Kelloff GJ), pp. 19-39. CRC Press, Boca Raton, 1992.
43. Pezzuto JM, Cancer chemopreventive agents: From plant materials to clinical intervention trials. In: Human Medicinal Agents from Plants (ACS Symposium Series No. 534) (Eds. Kinghorn AD and Balandrin ME), pp. 205-217. American Chemical Society Books, Washington, DC, 1993.
44. Shamon L and Pezzuto JM, Plant antimutagens: A review and strategy for the identification of therapeutically useful agents. In: Economic and Medicinal Plant Research (Eds. Farnsworth NR and Wagner H), Vol. 6, pp. 235-297. Academic Press, London, 1994.
45. Cassady JM, Zennie TM, Chae Y-H, Ferin MA, Portuondo NE and Baird WM, Use of mammalian cell culture benzo(a)-pyrene metabolism assay for the detection of potential anti-carcinogens from natural products: Inhibition of metabolism by biochanin A, and isoflavone from Trifolium pratense L. Cancer Res 48: 6257-6261, 1988.
46. Muto Y, Ninomiya M and Fujiki H, Present status of research on cancer chemoprevention in Japan. Jpn J Clin Oncol 20: 219-224, 1990.
47. Bertram JS, Hossain MZ, Pung A and Rundhaug JE, Development of in vitro systems for chemopreventive research. Prev Med 18: 562-575, 1989.
48. Sharma S, Stutzman JD, Kelloff GJ and Steele VE, Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res 54: 5848-5855, 1994.
49. Heller J, Catch-22. Simon & Schuster, New York, 1961.
50. Pezzuto JM, Natural product cancer chemopreventive agents. In: Recent Advances in Phytochemistry (Eds. Arnason JT, Mata R and Romeo JT), Vol. 29, pp. 19-45. Plenum Press, New York, 1995.
51. Gerhäuser C, Mar W, Lee SK, Suh N, Luo Y, Kosmeder J, Moriarty RM, Luyengi L, Kinghorn AD, Fong HHS, Mehta RG, Constantinou A, Moon RC and Pezzuto JM, Rotenoids mediate potent chemopreventive activity through transcrip-tional regulation of ornithine decarboxylase. Nature Med 1: 260-266, 1995.
52. Mehta RG, Liu J, Constantinou A, Thomas CF, Hawthorne M, You M, Gerhäuser C, Pezzuto JM, Moon RC and Moriarty RM, Cancer chemopreventive activity of brassinin, a phytoalexin from cabbage. Carcinogenesis 16: 399-404, 1995.
53. Jang M, Cai L, Udeani GO, Slowing-Barillas K, Thomas CF, Beecher CWW, Fong HHS, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC and Pezzuto JM, Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, in press.
54. Pisha E, Chai H, Lee I-S, Chagweder TE, Farnsworth NR, Cordell GA, Beecher CWW, Fong HHS, Kinghorn AD, Brown DM, Wani MC, Wall ME, Hieken TJ, Das Gupta TK and Pezzuto JM, Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nature Med 1: 1046-1051, 1995.
55. Gould MN, Prevention and therapy of mammary cancer by monoterpenes. J Cell Biochem S22: 139-144, 1995.
56. De Flora S, Bagnasco M and Zanacchi P, Classification and mechanism of action of cancer chemopreventive agents. In: Progress and Perspectives in Chemoprevention of Cancer, Serono Symposia Publications from Raven Press (Eds. De Palo G, Sporn M and Veronesi U), Vol. 79, pp. 1-11. Raven Press, New York, 1992.
57. Committee on Comparative Toxicity of Naturally Occurring Carcinogens, Carcinogens and Anticarcinogens in the Human Diet. National Academy Press, Washington, DC, 1996.
58. Milken calls for renewed war on cancer, $20 billion a year international effort. Cancer Lett. 21: 1-7, 1995.
59. Ziegler RG, Colavito EA, Nartge P, McAdams MJ, Schoenberg JB, Mason TJ and Fraumeni JF, Jr, Importance of α-carotene, β-carotene, and other phytochemicals in the etiology of lung cancer. J Natl Cancer Inst 88: 612-615, 1996.
60. Long-Term Tamoxifen Treatment for Breast Cancer. Jordan VC (Ed.), University of Wisconsin Press, Madison, 1994.
61. Powles TJ and Hickish T, Tamoxifen therapy and carcinogenic risk. J Natl Cancer Inst 87: 1343-1345, 1995.
62. Han XL and Liehr JG, Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52: 1360-1363, 1992.
63. Greaves P, Goonetilleke R, Nunn G, Topham J and Orton T, Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53: 3919-3924, 1993.
64. Jordan VC, Tamoxifen and carcinogenicity: A predictable concern. J Natl Cancer Inst 87: 623-626, 1995.